electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine company (the Company), today announced the release of an article entitled “gammaCore for Cluster Headaches: A NICE Medical Technologies Guidance” in the journal PharmacoEconomics highlighting the cost impact of gammaCore’s non-invasive vagus nerve stimulation therapy platform for patients with cluster headaches.
The paper is part of a series that provides insight into the development of UK National Institute for Health and Care Excellence (NICE) medical technologies guidance for new or innovative medical devices or diagnostics. The aim of the guidance is to support the adoption of clinically effective and cost-saving technologies in the UK National Health Service. The paper validated that gammaCore both reduces the frequency and severity of cluster headaches when used with standard of care and provides a £450 per patient savings in the first year of therapy versus standard of care alone.
“PharmacoEconomics reiterating the evidence supporting gammaCore’s effectiveness and economic benefit provides further support that gammaCore can play an important role in providing value-based therapy” commented Iain Strickland, VP Global Sales and Strategy of electroCore. “We look forward to the growth of our UK business as we continue to educate prescribers and payers on both the NICE medical technologies guidance and the MedTech Funding Mandate policy throughout the year. ”
The article can be accessed at: https://link.springer.com/article/10.1007/s41669-021-00276-5
